Precision Medicine for Inflammatory Treatment for Alzheimer's Disease in Down Syndrome
- Institution
- UNIVERSITY OF SOUTHERN CALIFORNIA, CA
- Principal investigator
- Robert Rissman
- Funding
- $604K
- Duration
- 2021–2026
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY/ABSTRACT Down syndrome (DS) is the most common genetic cause of intellectual disability, with virtually all DS individuals having AD by age 60. Despite exciting advances over the past 20 years in our understanding of DS and how genetics confer susceptibility for AD, there have been few clinical trials to treat AD in the DS population (DS-AD) and currently no means to clinically impact disease progression. We hypothesize that the biological makeup of DS-AD is as heterogeneous as the sporadic AD population and that identifying specific subsets of DS-AD for particular treatments will yield meaningful therapeutic responses. We propose to test a validated biomarker for sporadic AD, our established proinflammatory endophenotype analysis. This analysis will allow for an understanding of differences in immune signaling between DS-AD individuals and how this may impact anti- inflammatory effects on AD biomarkers. For this study we will leverage biobanked samples from the previously completed Phase 3 clinical trial, “Vitamin E in Aged Persons with Down Syndrome (NCT00056329).” For our proposed work we will employ high throughput proteomics on native plasma and exosome subpopulations to validate new techniques and develop a framework for designing better therapeutic trials for DS-AD
Research team
- Michael S RafiiPI
- Robert RissmanPI
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF SOUTHERN CALIFORNIA
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Medical University of South CarolinaNot yet scored
Life’s end Benefits of CannaBidiol and TetrahYdrocannabinol (LiBBY) Open-Label Extension (OLE) Study
Paul S. Aisen · $2.1M · 2025–2028
- NIH · University of Southern CaliforniaNot yet scored
Impact of Ethnicity on the Utility of Plasma Amyloid and Tau to Predict Alzheimer's Disease
Melissa Petersen · $582K · 2024–2029
- NIH · University of Southern CaliforniaNot yet scored
Novel Systemic Delivery of Peptide-Mediated Anti-Sense Oligonucleotides for Dementia with Lewy Bodies
Robert Rissman · $485K · 2021–2026